Congestive Heart Failure: Fifty Years of Progress
暂无分享,去创建一个
[1] M. Pfeffer,et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial , 2000, The Lancet.
[2] A. Katz. Cytoskeletal abnormalities in the failing heart: out on a LIM? , 2000, Circulation.
[3] P. Caroni,et al. Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure. , 2000, Circulation.
[4] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[5] B. Chandrasekar,et al. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. , 2000, Circulation.
[6] J. Molkentin,et al. Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. , 2000, Circulation.
[7] Y. Zou,et al. Ca2+/Calmodulin-dependent Kinase II and Calcineurin Play Critical Roles in Endothelin-1-induced Cardiomyocyte Hypertrophy* , 2000, The Journal of Biological Chemistry.
[8] G. Dorn,et al. Polymorphisms of the β2-Adrenergic Receptor Determine Exercise Capacity in Patients With Heart Failure , 2000 .
[9] L. Leinwand,et al. Myosin heavy chain isoform expression in the failing and nonfailing human heart. , 2000, Circulation research.
[10] M. Bristow. β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .
[11] L. Mestroni,et al. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. , 2000, Circulation.
[12] H. Sabbah,et al. Apoptotic cell death in heart failure. , 2000, Cardiovascular research.
[13] T. Negri,et al. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by β sarcoglycan mutations , 2000, Journal of medical genetics.
[14] J. Schaper,et al. The role of the cytoskeleton in heart failure. , 2000, Cardiovascular research.
[15] A. Marian. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy , 2000, The Lancet.
[16] ICHAEL,et al. THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE , 2000 .
[17] M. Bristow. b-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .
[18] J. Seidman,et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. , 1999, The New England journal of medicine.
[19] M. Thibonnier,et al. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. , 1999, Hypertension.
[20] G. Noon,et al. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery. , 1999, Circulation.
[21] K. Münter,et al. Endothelin-1 and Endothelin Receptor Antagonists in Cardiovascular Remodeling , 1999 .
[22] P. Burch,et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. , 1999, Circulation.
[23] B. Bozkurt,et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. , 1999, Circulation.
[24] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[25] R. Schwinger,et al. Reduced Ca2+-Sensitivity of SERCA 2a in Failing Human Myocardium due to Reduced Serin-16 Phospholamban Phoshorylation , 1999 .
[26] S. Lehnart,et al. Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. , 1999, Circulation.
[27] G. King,et al. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. , 1999, Circulation.
[28] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[29] R. Schwinger,et al. Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. , 1999, Journal of molecular and cellular cardiology.
[30] Y. Sun,et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.
[31] T. McIntosh,et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. , 1998, The Journal of clinical investigation.
[32] J. Cohn,et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. , 1998, European heart journal.
[33] S. Houser,et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. , 1998, Circulation.
[34] S. Thibodeau,et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. , 1998, Science.
[35] E. Braunwald,et al. Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. , 1998, Circulation.
[36] Jeffrey Robbins,et al. A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.
[37] R. Peshock,et al. Cardiac Failure in Transgenic Mice With Myocardial Expression of Tumor Necrosis Factor-α , 1998 .
[38] R. Peshock,et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. , 1998, Circulation.
[39] F. Clubb,et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.
[40] J. Towbin,et al. The role of cytoskeletal proteins in cardiomyopathies. , 1998, Current opinion in cell biology.
[41] P. Stiegler,et al. Pacing-induced heart failure in dogs enhances the expression of p53 and p53-dependent genes in ventricular myocytes. , 1998, Circulation.
[42] M. Packer,et al. MULTICENTER, DOUBLEBLIND PLACEBO CONTROLLED STUDY OF LONG TERMENDOTHELIN BLOCKADE WITH BOSENTAN IN CHRONIC HEART FAILURE RESULTS OF THE REACH-1 TRIAL. ABSTRACT , 1998 .
[43] C. E. Seidman,et al. Molecular genetic studies of familial hypertrophic cardiomyopathy , 1998, Basic Research in Cardiology.
[44] Y. Murakami,et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[45] M. Bristow. Mechanism of action of beta-blocking agents in heart failure. , 1997, The American journal of cardiology.
[46] K. Weber,et al. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. , 1997, Circulation.
[47] S. Chugh,et al. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. , 1997, Circulation.
[48] L. Leinwand,et al. Myosin heavy chain gene expression in human heart failure. , 1997, The Journal of clinical investigation.
[49] B. Groves,et al. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. , 1997, The Journal of clinical investigation.
[50] S. Neubauer,et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. , 1997, Circulation.
[51] A. Koretsky,et al. Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .
[52] M. Weiner,et al. Thyroid hormone improves function and Ca2+ handling in pressure overload hypertrophy. Association with increased sarcoplasmic reticulum Ca2+-ATPase and alpha-myosin heavy chain in rat hearts. , 1997, The Journal of clinical investigation.
[53] F. Lallemand,et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. , 1997, Circulation.
[54] B. Lorell,et al. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. , 1997, Circulation.
[55] G. Mancia,et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. , 1997, Circulation.
[56] G. King,et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[57] G. Beller,et al. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. , 1997, Circulation.
[58] G. Dorn,et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice , 1997 .
[59] A. Struthers,et al. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. , 1997, Cardiovascular research.
[60] W. Lederer,et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. , 1997, Science.
[61] E. Lakatta,et al. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. , 1997, The American journal of physiology.
[62] M. Böhm,et al. Changes in essential myosin light chain isoform expression provide a molecular basis for isometric force regulation in the failing human heart. , 1997, Journal of molecular and cellular cardiology.
[63] M. Oz,et al. Bridge experience with long-term implantable left ventricular assist devices. Are they an alternative to transplantation? , 1997, Circulation.
[64] M. Swindle,et al. Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine. , 1997, Circulation.
[65] Minoru Hongo,et al. MLP-Deficient Mice Exhibit a Disruption of Cardiac Cytoarchitectural Organization, Dilated Cardiomyopathy, and Heart Failure , 1997, Cell.
[66] M. Elam,et al. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. , 1997, Circulation.
[67] B. Lowes,et al. Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin. , 1996, Circulation.
[68] W. Abraham,et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. , 1996, Circulation.
[69] M. Bristow,et al. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. , 1996, Circulation.
[70] R. Virmani,et al. Apoptosis in myocytes in end-stage heart failure. , 1996, The New England journal of medicine.
[71] J. Ingwall,et al. Creatine kinase system in failing and nonfailing human myocardium. , 1996, Circulation.
[72] B. Beutler,et al. The tumor necrosis factor ligand and receptor families. , 1996, The New England journal of medicine.
[73] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[74] G. Maurer,et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. , 1996, Journal of the American College of Cardiology.
[75] D. Mann,et al. Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .
[76] K. M. McDonald,et al. Bioenergetic consequences of left ventricular remodeling. , 1995, Circulation.
[77] K. Mikoshiba,et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. , 1995, Circulation.
[78] B. Kay,et al. Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart. , 1995, Circulation research.
[79] B. Witzenbichler,et al. Antibody-mediated imbalance of myocardial energy metabolism. A causal factor of cardiac failure? , 1995, Circulation research.
[80] T. Doetschman,et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. , 1994, Circulation research.
[81] P. McCollam,et al. Role of microtubules in contractile dysfunction of hypertrophied cardiocytes. , 1994, Circulation.
[82] Y. Yazaki,et al. Intracellular signaling pathways in cardiac myocytes induced by mechanical stress. , 1994, Trends in cardiovascular medicine.
[83] R. Lefkowitz,et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. , 1994, Science.
[84] R. Lefkowitz,et al. Enhanced Myocardial Function inTransgenic Mice Overexpressing theP2-Adrenergic Receptor , 1994 .
[85] M. Bristow. Changes in myocardial and vascular receptors in heart failure. , 1993, Journal of the American College of Cardiology.
[86] D. Renlund,et al. Lisinopril Lowers Cardiac Adrenergic Drive and Increases, 8‐Recept or Density in the Failing Human Heart , 1993, Circulation.
[87] B. Lorell,et al. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. , 1993, Circulation research.
[88] J. Cohn,et al. Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure Relations to Survival and the Effects of Therapy in V‐HeFT II , 1993, Circulation.
[89] M. Böhm,et al. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. , 1993, Circulation.
[90] M. Lohse,et al. Altered Expression of, ‐Adrenergic Receptor Kinase and 1‐Adrenergic Receptors in the Failing Human Heart , 1993 .
[91] J. Ingwall. Is cardiac failure a consequence of decreased energy reserve , 1993 .
[92] K E Muffly,et al. Structural Remodeling of Cardiac Myocytes in Patients With Ischemic Cardiomyopathy , 1992, Circulation.
[93] E Erdmann,et al. Intracellular Calcium Handling in Isolated Ventricular Myocytes From Patients With Terminal Heart Failure , 1992, Circulation.
[94] T. Rector,et al. Endothelium‐Dependent Vasodilation Is Attenuated in Patients With Heart Failure , 1991, Circulation.
[95] G Olivetti,et al. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. , 1991, Circulation research.
[96] K. Swedberg,et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.
[97] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.
[98] B. Nadal-Ginard,et al. Molecular basis of cardiac performance. Plasticity of the myocardium generated through protein isoform switches. , 1989, The Journal of clinical investigation.
[99] P. Allen,et al. Changes in Myofibrillar Content and Mg‐ATPase Activity in Ventricular Tissues From Patients with Heart Failure Caused by Coronary Artery Disease, Cardiomyopathy, or Mitral Valve Insufficiency , 1988, Circulation research.
[100] S. Whitebread,et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. , 1987, The Journal of pharmacology and experimental therapeutics.
[101] B. Swynghedauw. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. , 1986, Physiological reviews.
[102] P. Korner,et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. , 1986, Circulation.
[103] J. Gwathmey,et al. Altered calcium handling in experimental pressure-overload hypertrophy in the ferret. , 1985, Circulation research.
[104] H. Krayenbuehl,et al. Relationship between myosin isoenzyme composition, hemodynamics, and myocardial structure in various forms of human cardiac hypertrophy. , 1985, Circulation research.
[105] R. Bing. The biochemical basis of myocardial failure. , 1983, Hospital practice.
[106] E. Braunwald,et al. The Stunned Myocardium: Prolonged, Postischemic Ventricular Dysfunction , 1982, Circulation.
[107] D C Harrison,et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.
[108] N. Alpert,et al. Functional significance of altered myosin adenosine triphosphatase activity in enlarged hearts. , 1979, The American journal of cardiology.
[109] I. Leusen,et al. Depression of regional blood flow and wall thickening after brief coronary occlusions. , 1978, The American journal of physiology.
[110] W Grossman,et al. Wall stress and patterns of hypertrophy in the human left ventricle. , 1975, The Journal of clinical investigation.
[111] Griggs Dm,et al. Subendocardial anaerobic metabolism in experimental aortic stenosis. , 1973 .
[112] G. Whipple,et al. Congestive heart failure following chronic tachycardia. , 1971, American heart journal.
[113] E. Braunwald,et al. Contractile State of Cardiac Muscle Obtained from Cats with Experimentally Produced Ventricular Hypertrophy and Heart Failure , 1967, Circulation research.
[114] E. Braunwald,et al. Myocardial High Energy Phosphate Stores in Cardiac Hypertrophy and Heart Failure , 1967, Circulation research.
[115] E. Braunwald,et al. MYOCARDIAL NOREPINEPHRINE CONCENTRATION IN MAN. EFFECTS OF RESERPINE AND OF CONGESTIVE HEART FAILURE. , 1963, The New England journal of medicine.
[116] Harold T. Dodge,et al. Left Ventricular Tension and Stress in Man , 1963, Circulation research.
[117] E. Braunwald,et al. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. , 1962, The New England journal of medicine.
[118] G E BURCH,et al. The George Fahr Lecture: Certain Mechanical Peculiarities of the Human Cardiac Pump in Normal and Diseased States , 1952, Circulation.
[119] W. Raab,et al. Heart "Sympathin" , 1950 .
[120] T. Clark,et al. The Prolonged Use of an Oral Mercurial Diuretic in Ambulatory Patients with Congestive Heart Failure , 1950 .
[121] T. R. Harrison,et al. Experimental Hypervolemic Heart Failure: Its Bearing on Certain General Principles of Heart Failure , 1950, Circulation.
[122] M. I. Ferrer,et al. Some Effects of Digoxin upon the Heart and Circulation in Man: Digoxin in Chronic Cor Pulmonale , 1950, Circulation.
[123] G. Nylin,et al. Determination of Blood Volume in the Heart and Lungs and the Cardiac Output through the Injection of Radiophosphorus , 1950, Circulation.